Death ligands such as tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and certain forms of CD95L are attractive therapeutic options for metastatic melanoma. Since knowledge about the regulation of death receptor sensitivity in melanoma is sparse, we have analysed these signaling pathways in detail. The loss of CD95 or TRAIL-R1, but not of TRAIL-R2, surface expression correlated with apoptosis sensitivity in a panel of melanoma cell lines. In contrast, the expression of proteins of the apical apoptosis signaling cascade (FADD, initiator caspases-8 and cFLIP) did not predict apoptosis sensitivity. Since both TRAIL-R1 and -R2 transmit apoptotic signals, we asked whether cFLIP, highly expressed in several of the cell lines tested, is sufficient to maintain resistance to TRAIL-R2-mediated apoptosis. Downregulation of cFLIP in TRAIL-R2-positive, TRAILresistant IGR cells dramatically increased TRAIL sensitivity. Conversely ectopic expression of cFLIP in TRAIL-sensitive, TRAIL-R2-expressing RPM-EP melanoma cells inhibited TRAIL-and CD95L-mediated cell death. Thus, modulation of cFLIP is sufficient to sensitize TRAIL-R2-expressing cells for TRAIL. Taken together, albeit expressing all proteins necessary for death receptormediated apoptosis, TRAIL-R1 negative melanoma cells cannot undergo TRAIL-or CD95L-induced apoptosis due to expression of cFLIP. Hence, cFLIP represents an attractive therapeutic target for melanoma treatment, especially in combination with TRAIL receptor agonists.
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Keywords: apoptosis; TRAIL; cFLIP; TRAIL-R1; TRAIL-R2; melanoma Malignant melanoma is a highly aggressive cancer with increasing incidence worldwide. Its capacity to metastasize at early stages and the resistance to chemotherapeutic agents results in overall poor prognosis of melanoma patients once metastasis has occurred (Miller and Mihm, 2006) . Similar to other cancer cell types, melanoma cells acquire apoptosis resistance during tumor progression. Death ligands are members of the tumor necrosis factor (TNF) superfamily of cytokines that can promote apoptosis via ligation of their corresponding death receptors. The proapoptotic functions of these death receptor-ligand systems have generated substantial interest in exploiting these death ligands for the killing of cancer cells (Takeda et al., 2007) . However, the contribution of death receptormediated signals for tumor initiation, promotion or metastasis as well as the regulation of genuine or acquired sensitivity to death ligands is currently unresolved in melanoma.
The TNF-related apoptosis-inducing ligand (TRAIL) is a ligand with high potential for the selective induction of apoptosis in transformed cells. TRAIL is able to bind to the receptors TRAIL receptor 1 (TRAIL-R1) and TRAIL-R2 that activate caspase-dependent apoptotic signaling cascades via their intracellular death domain. Additionally TRAIL binds to three other receptors, namely TRAIL-R3, TRAIL-R4 and the soluble osteoprotegerin (Falschlehner et al., 2007) . The CD95 ligand (CD95L) is another death ligand promoting apoptosis through binding to its receptor CD95 (Peter et al., 2007) . Both death ligands induce apoptosis by formation of a death-inducing signaling complex (DISC) at their respective death receptors that includes recruitment of the adapter molecule FADD as well as the initiator caspase-8 and caspase-10 ( Sprick and Walczak, 2004) . Caspase-8 is activated in the DISC and released, leading to subsequent cleavage of effector caspases such as caspase-3 that finally induce the morphological and structural changes of cell death by cleavage of a large variety of cellular substrates. Adding to the complexity, there is crosstalk between the death receptor (extrinsic) signaling pathway and the mitochondrial (intrinsic) signaling pathway. This fact is exemplified by substantial cell type-specific differences when the contribution of mitochondrial pathways (controlled by Bcl-2 family proteins) is explored in more detail. Importantly, Bcl-2 may protect against TRAIL-mediated apoptosis in a dose-dependent manner, in particular when suboptimal concentrations of TRAIL are used. These data point to a subtle regulation of death receptor sensitivity based upon the expression profile of distinct Bcl-2 family members (Rudner et al., 2005) . Likewise there is a strict requirement for proapoptotic multidomain Bcl-2 family proteins such as Bax and Bak in type II cells that require mitochondrial apoptotic signaling (Wendt et al., 2005; Neise et al., 2007) .
The cellular FLICE-like inhibitory protein (cFLIP) regulates death receptor-mediated apoptosis (Kataoka 2005) . cFLIP inhibits CD95-and TRAIL-R-mediated apoptosis by interfering with activation of caspase-8 at the DISC. Most studies have identified two splice variants of cFLIP at the protein level, cFLIP long (cFLIP L ) and cFLIP short (cFLIP S ). cFLIP L contains two death effector domains (DEDs) and a catalytically inactive caspase-like domain. In contrast, cFLIP S and cFLIP R , another splice variant of cFLIP, lack the caspase-like domain and inhibit death-receptormediated apoptosis by inhibition of procaspase-8 activation at the DISC (Golks et al., 2005) , while the role of cFLIP L in the DISC is more controversially discussed (Kataoka 2005) . In this report we have studied the mechanisms of resistance of human melanoma cells to TRAIL and CD95L-induced apoptosis. The surface expression of TRAIL-R1 and CD95, but not TRAIL-R2 largely correlated with death ligand resistance. Analysis of intracellular signaling pathways of apoptosis revealed mostly homogeneous expression of FADD, while caspase-8 and cFLIP expression levels were highly variable. Increasing cFLIP protein expression was sufficient to confer resistance to death ligands in previously sensitive melanoma cells. Conversely, decreasing the expression of cFLIP by RNA interference was sufficient to sensitize resistant melanomas to TRAIL-or CD95L-mediated apoptosis. Taken together our data demonstrate that TRAIL-R2 might be an attractive therapeutic target for TRAIL-agonistic therapeutic approaches, but may require additional targeted therapy to abrogate cFLIP expression.
We examined a panel of 10 genetically heterogeneous melanoma cell lines as well as primary human melanocytes (Mel) and first correlated cell surface expression of TRAIL-Rs and CD95 with death ligand sensitivity. We observed a heterogeneous surface expression pattern of death receptors. The loss of CD95 surface expression was tightly correlated with resistance to CD95L, however, CD95 expression did not predict sensitivity to the ligand (Figure 1a) . With the exception of RPM-MC and Mel, resistance to TRAIL-mediated apoptosis correlated with low or absent TRAIL-R1 surface expression (as exemplified by SK-Mel, Preyer, MeWo, IGR and MM-AN). Remarkably, all melanoma cell lines expressed TRAIL-R2 on their surface. Surface expression of TRAIL-R3 and TRAIL-R4 was largely absent with minor reproducible staining of TRAIL-R4 in IGR, MM-RU, MM-LH and MeWo. However PM-WK, RPM-MC, MM-RU and MM-LH and Mel expressed both TRAIL-R1 and TRAIL-R2 but showed either resistance (RPM-MC, Mel) or sensitivity (PM-WK, MM-RU, MM-LH). Taken together our data indicated that in significant subgroups of melanoma cells, loss of CD95 and TRAIL-R1, but not TRAIL-R2 surface expression correlated with CD95L or TRAIL resistance, supporting recently published data (Kurbanov et al., 2007) . More importantly, our results suggested that additional mechanisms of resistance beyond surface expression of death receptors must exist in melanoma cells.
A broad body of evidence suggested that modulation of DISC-recruited molecules such as FADD, caspase-8 or cFLIP determine sensitivity of death receptorexpressing cells to TRAIL and to CD95L (for review see Kataoka, 2005) . Thus differences in the expression of these molecules could impact both TRAIL and CD95 signaling in melanoma cells. Therefore we analysed protein expression of FADD, caspase-8, cFLIP, the major effector caspase-3 as well as regulators of the intrinsic apoptotic signaling pathway implicated in melanoma apoptosis resistance by other reports (APAF-1, Bcl-2, Bcl-X L , Bax, Bak and Bid). When compared to Mel, melanoma cells exhibited a remarkably heterogeneous expression pattern for cFLIP L , cFLIP S and caspase-8, whereas FADD and caspase-3 were mainly expressed at similar levels. Furthermore, expression levels of several Bcl-2 family members did not correlate with death receptor sensitivity. Notably, APAF-1 was homogenously expressed at largely comparable levels (Figure 1b) . Combining the data for surface expression, sensitivity and expression of cFLIP and caspase-8, we noted that the ratio of caspase-8 and cFLIP correlated with TRAIL sensitivity in cells that solely express TRAIL-R2 on the surface; RPM-EP cells were sensitive to TRAIL-induced apoptosis, expressed low levels of cFLIP and higher levels of caspase-8, while TRAIL-resistant IGR expressed slightly higher cFLIP L , markedly increased cFLIP S and substantially less caspase-8 (Figure 1b) . In contrast, the TRAIL-resistant melanoma lines Preyer and MeWo were not only deficient for TRAIL-R1 and cFLIP, but also showed the lowest expression levels of caspase-8 as well as the highest level of FADD within our panel. These data potentially explained the cFLIP-independent TRAIL resistance of Preyer and MeWo cell lines. Taken together, our data showed that there are multiple levels of death receptor apoptosis resistance in melanoma cells that include (1) surface expression of the receptor, (2) expression of caspase-8 and (3) expression of cFLIP isoforms in our panel of melanoma cells. Thus our results showed that albeit necessary, the expression of death receptors is not sufficient and decisive for apoptosis induction by CD95L and TRAIL. We concluded that due to its highly heterogeneous expression, the ratio of cFLIP and caspase-8 may represent the crucial determinant of death ligand apoptosis sensitivity of melanoma cells, in particular when tumor cells express at least one death receptor on their surface. (Byers et al., 1991) . Preyer melanoma cells had been generated from a subcutaneous melanoma metastasis. A375 (ATCC CRL-1619), MeWo (ATCC HTB-65), SK-Mel-30 (SK-Mel; ACC 151) and IGR-37 (IGR; ACC 237) were obtained from the indicated sources. Cells were cultured in complete DMEM (Gibco, Karlsruhe, Baden-Wu¨rttemberg, Germany), 4 mM L-glutamine, 4.5 g l À1 glucose, 10% fetal bovine serum (FCS Gold, PAA, Co¨lbe, Germany) and 1% penicillin/streptomycin (PAA). Primary melanocytes (Mel) were cultured in complete M2 melanocyte growth medium (PromoCell GmbH, Heidelberg, Germany). TRAIL-R1 -TRAIL-R4 and CD95 cell surface expression were determined by FACS analysis and stained with TRAIL-R1 (HS101), TRAIL-R2 (HS201), TRAIL-R3 (HS301), TRAIL-R4 (HS402) and CD95 (APO-1 IgG1) primary Abs (filled curves) as well as isotype-matched control Abs (open curves) exactly as described (Diessenbacher et al., 2007) . Death ligand sensitivity of cells was studied by stimulation of cells with TRAIL or CD95L for 18 h by crystal violet staining as described (Leverkus et al., 2003b) . LD50 (lethal dose of 50%) values represent the average of four independent experiments. His-FLAG-TRAIL (HF-TRAIL) was produced as published (Diessenbacher et al., 2007) . For expression of Fc-CD95L the coding sequence of human IgG1 (aa 247-472) was N-terminally fused to the extracellular portion of the CD95L (aa 117-281) and subcloned in a pcDNA3.1 vector with an N-terminal Igk-leader sequence. Protein was produced in transiently transfected 293 T cells using standard procedures. One unit of Fc-CD95L was determined as a 1:100 dilution of a stock Fc-CD95L supernatant, and was sufficient to kill 50 percent (LD50) of A375 melanoma cells. (b) The expression of FADD, FLIP, caspase-3, caspase-8, APAF, Bax and Bak from the cells indicated in (a) were determined by western blot analysis using antibodies (Abs) to caspase-8 (C-15), cFLIP (NF-6; Alexis, San Diego, CA, USA), FADD (Transduction Laboratories, San Diego, CA, USA), caspase-3 (CPP32, MF no. 393), Bax (sc-7480; Santa Cruz Biotechnologies Inc., Santa Cruz, CA, USA), Bak, Bcl-X L , Bcl-2 (BD Pharmingen, Heidelberg, Germany), Bid (rabbit serum, kindly provided by X Wang), Apaf-1 (RD Systems, Wiesbaden, Germany) and b-tubulin (Sigma, St Louis, MO, USA) as described (Leverkus et al., 2000) .
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We speculated that the differences of cFLIP could explain why TRAIL-R2 alone is sufficient to induce TRAIL-mediated apoptosis in RPM-EP, but not IGR cells. We therefore generated cell lines stably expressing cFLIP L -or cFLIP S (RPM-EP-cFLIP L and RPM-EPcFLIP S , respectively). The increase of cFLIP L and cFLIP S (Figures 2c and d) completely inhibited TRAIL-and CD95L-mediated apoptosis in RPM-EP cells (Figures 2a, b and f), while death receptor surface expression was unchanged (Figure 2e ). We next examined the activation and cleavage of cFLIP, caspase-8 and caspase-3 in these cells (Figures 2c and d) . TRAIL and CD95L efficiently induced caspase activation in RPM-EP cells as indicated by the cleavage of caspase-8 to the p18 fragment and cleavage of caspase-3 to p20 and p17 fragments. In contrast cleavage of caspase-8 and caspase-3 was largely reduced in RPM-EP-cFLIP L and RPM-EP-cFLIP S (Figures 2c and d) . In RPM-EP-cFLIP L , a p43 cleavage fragment of cFLIP L was observed after TRAIL and CD95L treatment. In addition, a cFLIP fragment of 22 kDa (p22) was detected in a stimulation-independent manner. In cells expressing cFLIP S , three additional fragments (p37, p33 and p22) recognized by the cFLIP-specific antibody were detected (Figures 2c and d) . We did not detect cleavage of endogenous cFLIP L in TRAIL-or CD95L-stimulated RPM-EP-cFLIP S , indicating that cFLIP S interferes with caspase-8 activity. We next examined the recruitment to and activation of caspase-8 in the DISC of these cells. FADD recruitment to the DISC did not significantly differ between parental cells, RPM-EP-cFLIP L or RPM-EPcFLIP S (Figures 2g and h) ) for 3 h. Protein expression of FADD, cFLIP, caspase-3 and caspase-8 was determined by western blot analysis using the indicated Abs. Arrows indicate molecular weights of identified proteins.
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P Geserick et al DISC. A marked increased recruitment of cFLIP p43 was observed in RPM-EP-cFLIP L . Furthermore increased amounts of cleaved caspase-8 (p43/41) and decreased levels of procaspase-8 were found in the DISC of RPM-EPcFLIP L . In contrast, cFLIP S completely inhibited caspase-8 cleavage, but did not interfere with procaspase-8 recruitment to the DISC indicating that cFLIP S blocked procaspase-8 processing in the DISC. Interestingly, we detected small, but specific levels of p18 within the CD95L DISC of cFLIP L -expressing cells, while p18 was absent in cFLIP S -expressing cells. Thus, the previously described mechanism how cFLIP S inhibits DISC-associated caspase-8 inhibition of lymphoid cells is not cell-type specific (Krueger et al., 2001) . It is thus also relevant in melanoma cells and supports the conclusion that full cleavage of caspase-8 within the DISC is possible in the presence of cFLIP L but not cFLIP S , thereby extending a previous report (Lavrik et al., 2003) . In summary, our data demonstrate that cFLIP L and cFLIP S block TRAIL-and CD95L-induced apoptosis of RPM-EP melanoma cells and suggest that this inhibition mechanistically occurs by interference with full caspase-8 processing at (cFLIP S ) or release of active caspase-8 from (in case of cFLIP L ) the DISC. We next aimed to regulate endogenous levels of cFLIP in exclusively TRAIL-R2-positive melanoma (g and h) Cells were either stimulated with 2.5 mg ml À1 Flag-TRAIL (g) or CD95L-Fc (h) for 30 min. TRAIL or CD95L DISC was precipitated by ligand affinity precipitation as described previously using 5 Â 10 6 cells per condition (Wachter et al., 2004) . Precipitation of receptor complexes following lysis (À) served as internal specificity control when compared to ligand affinity precipitates (IP; þ ). A fraction of the lysates was used to control for the input of the respective proteins. Proteins were separated on 4-12% NuPAGE gradient gels (Invitrogen, Karlsruhe, Germany) before detection of DISC components by western blot analysis. (Figures 3a and f) . In addition, we noted increased sensitivity of IGR-cFLIP-siRNA to CD95L (LD50 3-6 ng ml À1 ; Figures 3b and f) , indicative of the broader role of cFLIP for TRAIL-and CD95 apoptosis resistance in melanoma. These data suggested that triggering of TRAIL-R2 is necessary and sufficient to induce TRAIL-mediated apoptotic cell death in melanoma cells when cFLIP is absent. Surface expression of TRAIL-Rs and CD95 was unchanged, indicating that downregulation of cFLIP is responsible for increased sensitivity to TRAIL and CD95L (Figure 3e ). We next investigated caspase activation in IGR-cFLIP-siRNA. Cells were treated with either TRAIL or CD95L and subsequently analysed for expression of cFLIP, caspase-8 and -3 (Figures 3c and d) . Control-infected cells stimulated with TRAIL or CD95L readily activated caspase-8, and endogenous cFLIP L was cleaved ( Figures  3c and d) . However processing of caspase-8 to the fully cleaved p18 fragment was undetectable. In contrast, stimulation with TRAIL or CD95L resulted in processing of caspase-8 and -3 in IGR-cFLIP-siRNA cells (Figures 3c and d) . We next performed TRAIL and CD95L DISC analysis in these cells. FADD recruitment to the TRAIL and CD95L DISC did not significantly differ between parental, control and cFLIP-knockdown IGR cells (Figures 3g and h) . In contrast downregulation of cFLIP led to decreased recruitment of p43 cFLIP, while increased recruitment of procaspase-8 (55/ 53) was observed in IGR-cFLIP-siRNA. These data suggest that cFLIP L increases the autocatalytic cleavage of caspase-8 in the DISC, while blocking the release of active caspase-8 from the DISC, therefore blocking the generation of high levels of caspase-8 outside of the DISC required for efficient effector-caspase activation (Krueger et al., 2001) . In several experiments, we were unable to detect caspase-8 p18 within the DISC, presumably due to the lower expression level in IGR cells (compare Figure 1b) . Taken together our results demonstrate that cFLIP is a crucial modulator of TRAIL-R2-mediated apoptosis at the DISC in malignant melanoma.
It is widely accepted that the balance of pro-and antiapoptotic proteins is critical for the cell fate decision of tumor cells (Meng et al., 2006) . Intriguingly, several examples of deregulated molecules involved in the activation of the intrinsic apoptotic signaling pathways in melanoma point to activation of the extrinsic apoptosis pathway as a promising target for melanoma treatment (for review see Karst and Li, 2007) . Importantly, there is evidence that melanoma cells may lack crucial components of the death machinery precluding efficient elimination by apoptosis. While the loss of Apaf-1 is controversially discussed (Allen et al., 2005; Peltenburg et al., 2005) , a loss of Bax and Bak (or other proapoptotic Bcl-2 family members of the BH3-only group) might well be relevant to predict death ligand sensitivity (for review see Karst and Li, 2007) . Thus TRAIL may be used alone or in combination with other drugs that overcome mitochondrial blockade against death receptor-mediated apoptosis in melanoma. Based on the molecular and biochemical data reported thus far, tumor cells that express of either TRAIL-R1 or TRAIL-R2 could be prone to ligand-mediated apoptosis. However, the differential roles of either TRAIL-R1 or TRAIL-R2 surface expression have not been extensively addressed under non-overexpressing conditions. In melanoma, controversial results for expression of TRAIL death receptors, cFLIP expression and its correlation to apoptosis sensitivity exist (Griffith et al., 1998; Zhang et al., 1999; Nguyen et al., 2001) , putting forth a detailed characterization of these signaling pathways in this report.
Our results extend the previous notion that primary melanocytes are resistant to TRAIL-mediated apoptosis despite high TRAIL-R1 and TRAIL-R2 expressions. It was suggested that TRAIL-R1 and TRAIL-R2 expressions are essentially required for sensitivity of melanomas to TRAIL-induced apoptosis (Ivanov et al., 2003) . However it was controversially discussed whether TRAIL-R1 or TRAIL-R2 surface expression or coexpression of both death receptors is needed for TRAIL-induced cell death. Some authors found that TRAIL-R2 expression was associated with TRAIL sensitivity (Griffith et al., 1998) , while others suggested that TRAIL-R1 expression correlated better with apoptosis sensitivity to TRAIL-mediated apoptosis (Kurbanov et al., 2007) . Our study demonstrates that the expression pattern of TRAIL-R on melanoma cells is rather heterogeneous. Additionally we noted that most resistant melanoma cell lines lost TRAIL-R1 surface expression, potentially avoiding successful apoptosis induction of melanoma cells by TRAIL-R1-specific agonists. Our in vitro findings are supported by others that associated decreased expression of TRAIL-R1 and TRAIL-R2 with increased resistance to TRAIL-induced apoptosis of melanomas (Ivanov et al., 2003; Zhuang et al., 2006) . It will be interesting to determine TRAIL receptor expression in vivo, especially in larger patient collectives when a primary tumor can be compared to sentinel lymph node, lymph node metastasis as well as distant metastases.
Following the surprising observation that all melanoma cells expressed TRAIL-R2 and demonstrated highly variable levels of crucial intracellular molecules, our study determined that cFLIP is a critical regulator of death ligand sensitivity in melanoma. A number of studies suggested that TRAIL receptors TRAIL-R3 and TRAIL-R4 are involved in the regulation of TRAILmediated apoptosis (for review see Kimberley and Screaton, 2004) . However, our results for surface expression of TRAIL receptors suggested (1) no significant correlation with apoptosis resistance for TRAIL-R2, TRAIL-R3 and TRAIL-R4 in melanoma and (2) indicated that downstream of TRAIL binding, the death receptor signaling cascade may be inhibited either by deregulated expression of proapoptotic molecules or by intracellular apoptosis inhibitors or We used stable expression of cFLIP siRNA exactly as described (Diessenbacher et al., 2007) . The retrovirus-containing supernatant was used to infect IGR melanoma cells, and infected cells were selected with puromycin (1 mg ml
À1
; Sigma, Taufkirchen, Germany) for 3-7 days. The respective empty construct served as internal control. Parental, control-infected (Vector) or cFLIP siRNAtransduced IGR melanoma cells (IGR-cFLIP-siRNA) were stimulated with the indicated amounts of TRAIL or CD95L for 18 h. Viability was determined by crystal violet assay (a and b) or hypodiploidy analysis (f) (mean ± s.d. of four independent experiments). (c and d) Downregulation of cFLIP allows for caspase activation in TRAIL-and CD95L-stimulated IGR melanoma. Cells were stimulated with TRAIL (125 ng ml Suppression of cFLIP in melanoma cells P Geserick et al activators. Further adding to the complexity of the stoichiometric variation of different parts of the death signaling cascade, in some of the melanoma cell lines studied (Preyer, MeWo), a decrease of caspase-8 levels were found, that might explain the high resistance of these particular cell lines to TRAIL. Interestingly, the observed higher expression level of FADD in these cell lines does not overcome TRAIL and CD95L resistance in both cell lines, pointing to additional levels of complexity of death receptor resistance in melanoma. To this end, it will be intriguing to study if the loss of caspase-8 expression or other proteins of the apical death receptor cascade might be explained by epigenetic regulation as also reported for other neural crest-derived cells (Fulda et al., 2001; Bae et al., 2007) .
The molecular mechanism governing the ability of cFLIP isoforms to control apoptosis resistance in malignant melanoma is currently unresolved. Early studies confirmed that cFLIP protein expression did not correlate with TRAIL resistance in melanoma (Zhang et al., 1999) . In line, we identified variable cFLIP levels in our melanoma cells that did not generally correlate with TRAIL sensitivity, and indicate that dynamic regulation of cFLIP could potentially increase the TRAIL sensitivity of melanoma cells. By using a more specific regulation of cFLIP isoforms by shRNA and stable overexpression, our study demonstrates that cFLIP represents a crucial negative regulator of TRAIL-and CD95L-mediated apoptosis in a subgroup of melanoma cells. The fact that cFLIP L or cFLIP S efficiently blocked TRAIL-and CD95L-induced cell death by modulation of caspase-8 activation at the DISC demonstrates that this process is critical in melanoma cells. We observed several differences in cFLIP L -versus cFLIP S -expressing cells: intermediate cleavage products of caspase-8 (p41/p43) and cFLIP L p43 were detected in the TRAIL as well as in the CD95L DISC, whereas the DISC of cFLIP S -expressing cells did not contain cleaved caspase-8. Our data corroborate previous reports that while cFLIP L activates autocatalytic cleavage of caspase-8 in the DISC, cFLIP S blocks procaspase-8 cleavage but does not preclude caspase-8 recruitment to the DISC (Krueger et al., 2001) . It is intriguing to hypothesize that different cFLIP isoforms might be able to differentially activate other signaling pathways following death receptor ligation such as nuclear factor-kB or MAPK in melanoma, ultimately resulting in activation of distinct sets of target genes that may facilitate tumor progression or metastasis, as recently reported in a pancreatic tumor model (Trauzold et al., 2006) . While cFLIP isoforms have been widely studied in respect to their anti-apoptotic function, our studies using cFLIP isoforms revealed several important details about a potential death receptor-independent role of these molecules. We observed p33 and p22 kDa bands reactive with the cFLIP antibody that was generated against the N terminus of cFLIP (Scaffidi et al., 1999) . Interestingly, whereas RPM-EP-cFLIP S contained 33 and 22 kDa fragments of cFLIP, in RPM-EP-cFLIP L only p22 was detected and this cFLIP L cleavage pattern is associated with DISC-independent enzymatic activity of procaspase-8 (Golks et al., 2006) . Our data thus indicated inhibition of procaspase-8 cleavage by cFLIP S , whereas basal cFLIP L cleavage into p33 and p22 kDa fragments suggests that cFLIP s does not interfere with DISC-independent enzymatic activity of procaspase-8. Future biochemical studies are required to delineate this point in more detail. We were not able to detect p22 of cFLIP L and cFLIP S in the TRAIL or CD95L DISC of cFLIP L -or cFLIP S -expressing melanoma cells, suggesting cell-type specific differences when compared to the published data (Golks et al., 2006) . In addition, it is tempting to speculate that such cFLIP fragments or uncleaved cFLIP L itself may modulate important apoptosis-independent signaling pathways such as Wnt (Naito et al., 2004) cytotoxic agents (Ivanov and Hei, 2006) or imatinib (Hamai et al., 2006) sensitized resistant melanomas to TRAIL-mediated apoptosis. However, transient transfection studies might be hampered by the activation of cellular responses due to toxic effects of the transfection procedure. Using stable short-term selected expression of cFLIP isoforms as well as stable retroviral knockdown we could clearly demonstrate that downregulation of cFLIP is sufficient to overcome TRAIL or CD95 resistance in melanoma cells. Our data indicate that upregulation of antiapoptotic or loss of proapoptotic Bcl-2 family proteins might be less relevant for death ligand resistance in melanoma, at least in the subset of melanoma lines studied in this report, although a loss of Bax and Bak has been found in primary melanomas in vivo (Fecker et al., 2006) . Nonetheless our data for the extrinsic apoptosis pathway demonstrate that interference with cFLIP expression in combination with TRAIL agonists could represent an attractive therapy for melanoma. Although any study using in vitro cultured cancer cell lines has its limitations, our finding that all cultured melanoma lines express TRAIL-R2 on their surface might have future clinical implications. Currently, TRAIL agonistic agents against TRAIL-R1 and TRAIL-R2 are developed and may demonstrate to be of value for the therapy of metastatic melanoma. Moreover, receptor-specific mutant forms of TRAIL (Kelley et al., 2005; Macfarlane et al., 2005; van der Sloot et al., 2006) or agonistic antibodies (Hymowitz and Ashkenazi 2005; Buchsbaum et al., 2007; Natoni et al., 2007) might prove clinically useful in this context in a tumor-type specific manner. Future studies will additionally have to address the requirement for crosslinking/multimerization of the different TRAIL-R by distinct agonists, as previously suggested (Muhlenbeck et al., 2000; Leverkus et al., 2003a) . Our data presented in this report indicate that in particular TRAIL-R2-specific agonists might be attractive candidates for melanoma treatment and that the regulation of cFLIP could be an additional target for future melanoma therapies.
